Dulaglutide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dulaglutide and local guidelines before prescribing.
GLP-1 receptor agonist
Mechanism
Once-weekly GLP-1 receptor agonist.
Uses
Type 2 diabetes with cardiovascular benefit.
Dosing
- Dulaglutide weekly: 0.75–1.5 mg and higher.
Endocrinology: Diabetes - Liraglutide / dulaglutide Type 2 | Liraglutide 0.6 mg daily, then 1.2–1.8 mg. Dulaglutide 0.75–1.5 mg weekly (higher doses available).
Endocrinology: Diabetes
Side effects
Nausea, diarrhoea, pancreatitis, injection-site reaction.
Interactions
Insulin and sulfonylureas hypoglycaemia.
Contraindications and cautions
Pancreatitis history
Monitoring
HbA1c, weight
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Weekly injection; titrate slowly.
More from the textbook: uses, cautions and other points
- Semaglutide, liraglutide and dulaglutide reduce cardiovascular events in people with cardiovascular disease.
Endocrinology: Diabetes
Where it is discussed in the book
- Endocrinology: Diabetes (3 mentions)